Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
This list of potential positions covers Addiction driven consumer products and services. Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol in USA. Please note, we provide buy hold or sell recommendation only in the context of selected investment horizon assuming investor has average attitude towards taking risk. Please also consider using Portfolio Positions Ratings and Equity Ratings tools to further calibrate your research.
Story appears to be empty
Anheuser Busch Inbev (BUD)
The company has Return on Asset of 0.0416 % which means that on every $100 spent on assets, it made $0.0416 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0779 %, implying that it generated $0.0779 on every 100 dollars invested. Anheuser Busch's management efficiency ratios could be used to measure how well Anheuser Busch manages its routine affairs as well as how well it operates its assets and liabilities. At present, Anheuser Busch's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. At present, Anheuser Busch's Asset Turnover is projected to slightly decrease based on the last few years of reporting. This firm currently falls under 'Mega-Cap' category with a total capitalization of 117.26 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Anheuser Busch's market, we take the total number of its shares issued and multiply it by Anheuser Busch's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Anheuser Busch Inbev shows a prevailing Real Value of $63.7 per share. The current price of the firm is $60.18. Our model approximates the value of Anheuser Busch Inbev from analyzing the firm fundamentals such as return on equity of 0.0779, and Profit Margin of 0.09 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Merck Company (MRK)
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 321.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merck's market, we take the total number of its shares issued and multiply it by Merck's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Tangible Asset Value is very stable compared to the past year. As of the 24th of April 2024, Intangibles To Total Assets is likely to grow to 0.60, while Total Current Assets are likely to drop about 15.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 217.43 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca PLC's market, we take the total number of its shares issued and multiply it by AstraZeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Sanofi ADR (SNY)
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024. This firm currently falls under 'Mega-Cap' category with a total capitalization of 117.71 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sanofi ADR's market, we take the total number of its shares issued and multiply it by Sanofi ADR's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 185.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Abbott Laboratories shows a prevailing Real Value of $110.3 per share. The current price of the firm is $107.59. Our model approximates the value of Abbott Laboratories from analyzing the firm fundamentals such as profit margin of 0.14 %, and Return On Equity of 0.15 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Novartis AG ADR (NVS)
The company has Return on Asset of 0.0727 % which means that on every $100 spent on assets, it made $0.0727 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1615 %, implying that it generated $0.1615 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novartis' Return On Tangible Assets are comparatively stable compared to the past year. Return On Capital Employed is likely to gain to 0.14 in 2024, whereas Return On Assets are likely to drop 0.11 in 2024. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.2 B in 2024, whereas Total Current Assets are likely to drop slightly above 29.9 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 195.98 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0322 % which means that on every $100 spent on assets, it made $0.0322 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.039 %, implying that it generated $0.039 on every 100 dollars invested. Disney's management efficiency ratios could be used to measure how well Disney manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.02 in 2024. Return On Capital Employed is likely to drop to 0.02 in 2024. At this time, Disney's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 208.7 B in 2024, whereas Other Assets are likely to drop slightly above 10.5 B in 2024. The entity currently falls under 'Mega-Cap' category with a total capitalization of 205.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Disney's market, we take the total number of its shares issued and multiply it by Disney's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Walt Disney shows a prevailing Real Value of $115.47 per share. The current price of the firm is $113.71. Our model computes the value of Walt Disney from reviewing the firm fundamentals such as Current Valuation of 250.7 B, return on equity of 0.039, and Operating Margin of 0.13 % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Yamana Gold (AUY)
The company has Return on Asset of (0.1288) % which means that on every $100 spent on assets, it lost $0.1288. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3137) %, meaning that it generated no profit with money invested by stockholders. Yamana Gold's management efficiency ratios could be used to measure how well Yamana Gold manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Mid-Cap' category with a total capitalization of 5.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Yamana Gold's market, we take the total number of its shares issued and multiply it by Yamana Gold's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Macroaxis financial leverage refers to using borrowed capital as a funding source to finance Macroaxis ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Macroaxis financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Macroaxis' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Macroaxis' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Macroaxis's total debt and its cash.
Story appears to be empty
Anheuser Busch Inbev (BUD)
The company has Return on Asset of 0.0416 % which means that on every $100 spent on assets, it made $0.0416 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0779 %, implying that it generated $0.0779 on every 100 dollars invested. Anheuser Busch's management efficiency ratios could be used to measure how well Anheuser Busch manages its routine affairs as well as how well it operates its assets and liabilities. At present, Anheuser Busch's Return On Capital Employed is projected to slightly decrease based on the last few years of reporting. At present, Anheuser Busch's Asset Turnover is projected to slightly decrease based on the last few years of reporting. This firm currently falls under 'Mega-Cap' category with a total capitalization of 117.26 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Anheuser Busch's market, we take the total number of its shares issued and multiply it by Anheuser Busch's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be undervalued. Anheuser Busch Inbev shows a prevailing Real Value of $63.7 per share. The current price of the firm is $60.18. Our model approximates the value of Anheuser Busch Inbev from analyzing the firm fundamentals such as return on equity of 0.0779, and Profit Margin of 0.09 % as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Merck Company (MRK)
The company has Return on Asset of 0.0264 % which means that on every $100 spent on assets, it made $0.0264 of profit. This is way below average. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.01. The value of Return On Capital Employed is expected to slide to 0.04. At this time, Merck's Non Current Liabilities Total is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 10.8 B this year, although the value of Total Current Liabilities will most likely fall to about 13.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 321.54 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Merck's market, we take the total number of its shares issued and multiply it by Merck's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.066 % which means that on every $100 spent on assets, it made $0.066 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1564 %, implying that it generated $0.1564 on every 100 dollars invested. AstraZeneca PLC's management efficiency ratios could be used to measure how well AstraZeneca PLC manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of April 2024, Return On Assets is likely to grow to 0.10, while Return On Tangible Assets are likely to drop 0.11. At this time, AstraZeneca PLC's Tangible Asset Value is very stable compared to the past year. As of the 24th of April 2024, Intangibles To Total Assets is likely to grow to 0.60, while Total Current Assets are likely to drop about 15.3 B. The entity currently falls under 'Mega-Cap' category with a total capitalization of 217.43 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AstraZeneca PLC's market, we take the total number of its shares issued and multiply it by AstraZeneca PLC's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Sanofi ADR (SNY)
The company has Return on Asset of 0.0454 % which means that on every $100 spent on assets, it made $0.0454 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0727 %, implying that it generated $0.0727 on every 100 dollars invested. Sanofi ADR's management efficiency ratios could be used to measure how well Sanofi ADR manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.14 in 2024. Return On Capital Employed is likely to rise to 0.17 in 2024. At this time, Sanofi ADR's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 77.3 B in 2024, whereas Total Assets are likely to drop slightly above 88.2 B in 2024. This firm currently falls under 'Mega-Cap' category with a total capitalization of 117.71 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sanofi ADR's market, we take the total number of its shares issued and multiply it by Sanofi ADR's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0611 % which means that on every $100 spent on assets, it made $0.0611 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1511 %, implying that it generated $0.1511 on every 100 dollars invested. Abbott Laboratories' management efficiency ratios could be used to measure how well Abbott Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Abbott Laboratories' Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.10 in 2024. At this time, Abbott Laboratories' Non Current Liabilities Other is comparatively stable compared to the past year. Change To Liabilities is likely to gain to about 44.7 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 8.3 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 185.79 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Abbott Laboratories's market, we take the total number of its shares issued and multiply it by Abbott Laboratories's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Abbott Laboratories shows a prevailing Real Value of $110.3 per share. The current price of the firm is $107.59. Our model approximates the value of Abbott Laboratories from analyzing the firm fundamentals such as profit margin of 0.14 %, and Return On Equity of 0.15 as well as examining its technical indicators and probability of bankruptcy. In general, most investors favor acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will blend.
Novartis AG ADR (NVS)
The company has Return on Asset of 0.0727 % which means that on every $100 spent on assets, it made $0.0727 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1615 %, implying that it generated $0.1615 on every 100 dollars invested. Novartis' management efficiency ratios could be used to measure how well Novartis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Novartis' Return On Tangible Assets are comparatively stable compared to the past year. Return On Capital Employed is likely to gain to 0.14 in 2024, whereas Return On Assets are likely to drop 0.11 in 2024. At this time, Novartis' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 73.2 B in 2024, whereas Total Current Assets are likely to drop slightly above 29.9 B in 2024. The firm currently falls under 'Mega-Cap' category with a total capitalization of 195.98 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Novartis's market, we take the total number of its shares issued and multiply it by Novartis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
The company has Return on Asset of 0.0322 % which means that on every $100 spent on assets, it made $0.0322 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.039 %, implying that it generated $0.039 on every 100 dollars invested. Disney's management efficiency ratios could be used to measure how well Disney manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.02 in 2024. Return On Capital Employed is likely to drop to 0.02 in 2024. At this time, Disney's Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 208.7 B in 2024, whereas Other Assets are likely to drop slightly above 10.5 B in 2024. The entity currently falls under 'Mega-Cap' category with a total capitalization of 205.42 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Disney's market, we take the total number of its shares issued and multiply it by Disney's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. At this time, the firm appears to be fairly valued. Walt Disney shows a prevailing Real Value of $115.47 per share. The current price of the firm is $113.71. Our model computes the value of Walt Disney from reviewing the firm fundamentals such as Current Valuation of 250.7 B, return on equity of 0.039, and Operating Margin of 0.13 % as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors advise acquiring undervalued instruments and selling overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
Yamana Gold (AUY)
The company has Return on Asset of (0.1288) % which means that on every $100 spent on assets, it lost $0.1288. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3137) %, meaning that it generated no profit with money invested by stockholders. Yamana Gold's management efficiency ratios could be used to measure how well Yamana Gold manages its routine affairs as well as how well it operates its assets and liabilities. This firm currently falls under 'Mid-Cap' category with a total capitalization of 5.63 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Yamana Gold's market, we take the total number of its shares issued and multiply it by Yamana Gold's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Please refer to our Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com
Did you try this?
Run Price Transformation Now
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any private could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
